Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
novartis
7
×
fda
national top stories
boston blog main
boston top stories
national
new york top stories
san francisco top stories
clinical trials
genentech
indiana blog main
indiana top stories
new york blog main
san francisco blog main
amgen
biogen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
europe top stories
gene therapy
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
europe blog main
ipo
roche
What
fda
7
×
new
drug
medicines
therapy
approval
bio
roundup
won
acquire
activity
address
agreed
amgen
approvals
approved
approves
atrophy
august
billion
biogen
biotech
blueprint
brings
busy
cancer
candidates
carries
cash
certain
chemistry
cholesterol
clamped
class
cmc
company
compound
consistent
controls
covid
Language
unset
Current search:
novartis
×
fda
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products
@xconomy.com
3 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines